- Successfully Closes $12M Public Offering, Strengthens Balance Sheet and Supports Anticipated U.S. Launch- Recent Peer-Reviewed Publication Demonstrates Advantages of Hybrid IVUS-OCT Imaging TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided a ...

Core Insights - The publication of new peer-reviewed research supports the clinical and commercial value of Conavi Medical's hybrid intravascular imaging platform, demonstrating its superiority in plaque characterization compared to single-modality analyses and human experts [1][2]. Group 1: Research Findings - The study analyzed IVUS-OCT images and matched histological sections from 10 cadaveric human hearts, showing that a histology-trained hybrid IVUS-OCT deep-learning classifier outperformed single-modality IVUS, single-modality OCT, and expert readers in plaque characterization [2]. - The research highlights the importance of comprehensive hybrid imaging systems in enhancing treatment planning for coronary interventions [2]. Group 2: Company Developments - Conavi Medical is advancing the development and commercialization of its next-generation hybrid IVUS-OCT imaging solutions, having submitted its Novasight imaging system to the U.S. FDA for regulatory clearance [4]. - The company has granted stock options to its Chief Financial Officer, Mark Quick, for a total of 1,000,000 common shares at an exercise price of $0.41 per share, as part of its long-term incentive program [5][6]. Group 3: Leadership and Expertise - The publication includes contributions from Dr. Brian Courtney, a pioneer in hybrid IVUS-OCT imaging, and co-authors from various regions, including Canada, Europe, and the USA, as well as AI researchers from Queen Mary University of London [3]. - The CEO of Conavi Medical, Tom Looby, emphasized the clinical value proposition of the technology platform and the significance of hybrid systems in the evolving field of image-guided coronary interventions [4]. Group 4: Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures, with its Novasight Hybrid™ System being the first to combine IVUS and OCT into a single device [7]. - The first-generation Novasight Hybrid™ System has received 510(k) regulatory clearance in the U.S., Canada, China, and Japan [7].